Alexander Schramm

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 26

Top Venues

Nature medicine

Cancers

Communications biology

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T W Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hanenberg, Sven Rahmann, Dietmar R Lohmann, Alexander Schramm, Petra Ketteler
Author Correction: A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology 7 (1) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T W Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hannenberg, Sven Rahmann, Dietmar R Lohmann, Alexander Schramm, Petra Ketteler
A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology 7 (1) (2024)
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T W Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hannenberg, Sven Rahmann, Dietmar R Lohmann, Alexander Schramm, Petra Ketteler
A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology 7 (1) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine (2024)
Tatsiana Ryl, Elena Afanasyeva, Till Hartmann, Melanie Schwermer, Markus Schneider, Christopher Schröder, Maren Wagemanns, Arthur Bister, Deniz Kanber, Laura Steenpass, Kathrin Schramm, Barbara Jones, David T W Jones, Eva Biewald, Kathy Astrahantseff, Helmut Hannenberg, Sven Rahmann, Dietmar R Lohmann, Alexander Schramm, Petra Ketteler
A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology 7 (1) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Janina Janetzko, Sebastian Oeck, Alexander Schramm
The Multifaceted Roles of Lamins in Lung Cancer and DNA Damage Response. Cancers 15 (23) (2023)
Nenad Maricic, Melanie Schwermer, Alexander Schramm, Gabriela Morosan-Puopolo, Petra Ketteler, Beate Brand-Saberi
Zebrafish as an Orthotopic Tumor Model for Retinoblastoma Mimicking Routes of Human Metastasis. Cancers 14 (23) (2022)
Kai Voeltzke, Katerina Scharov, Cornelius Maximilian Funk, Alisa Kahler, Daniel Picard, Laura Hauffe, Martin F Orth, Marc Remke, Irene Esposito, Thomas Kirchner, Alexander Schramm, Barak Rotblat, Thomas G P Grünewald, Guido Reifenberger, Gabriel Leprivier
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma. Cell death discovery 8 (1) (2022)
Clotilde Thumser-Henner, Sebastian Oeck, Sophie Kalmbach, Jan Forster, Franziska Kindl, Ali Sak, Alexander Schramm, Martin Schuler
Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer. Cell death & disease 13 (6) (2022)
Nenad Maricic, Melanie Schwermer, Alexander Schramm, Gabriela Morosan-Puopolo, Petra Ketteler, Beate Brand-Saberi
Zebrafish as an Orthotopic Tumor Model for Retinoblastoma Mimicking Routes of Human Metastasis. Cancers 14 (23) (2022)
Nenad Maricic, Melanie Schwermer, Alexander Schramm, Gabriela Morosan-Puopolo, Petra Ketteler, Beate Brand-Saberi
Zebrafish as an Orthotopic Tumor Model for Retinoblastoma Mimicking Routes of Human Metastasis. Cancers 14 (23) (2022)
Lukas Funke, Thilo Bracht, Sebastian Oeck, Karin Schork, Markus Stepath, Sabine Dreesmann, Martin Eisenacher, Barbara Sitek, Alexander Schramm
NTRK1/TrkA Signaling in Neuroblastoma Cells Induces Nuclear Reorganization and Intra-Nuclear Aggregation of Lamin A/C. Cancers 13 (21) (2021)
Christina Hassiepen, Aashish Soni, Ines Rudolf, Vivian Boron, Sebastian Oeck, George Iliakis, Alexander Schramm
NTRK1/TrkA Activation Overrides the G2/M-Checkpoint upon Irradiation. Cancers 13 (23) (2021)
Sebastian Oeck, Alicia Isabell Tüns, Sebastian Hurst, Alexander Schramm
Streamlining Quantitative Analysis of Long RNA Sequencing Reads. International journal of molecular sciences 21 (19) (2020)
Silke Nothdurft, Clotilde Thumser-Henner, Frank Breitenbücher, Ross A Okimoto, Madeleine Dorsch, Christiane A Opitz, Ahmed Sadik, Charlotte Esser, Michael Hölzel, Saurabh Asthana, Jan Forster, Daniela Beisser, Sophie Kalmbach, Barbara M Grüner, Trever G Bivona, Alexander Schramm, Martin Schuler
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis 9 (11) (2020)
Britta Tjaden, Katharina Baum, Viktoria Marquardt, Mareike Simon, Marija Trajkovic-Arsic, Theresa Kouril, Bettina Siebers, Jan Lisec, Jens Thomas Siveke, Johannes H Schulte, Uwe Benary, Marc Remke, Jana Wolf, Alexander Schramm
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma. Scientific reports 10 (1) (2020)
Sandra Ackermann, Maria Cartolano, Barbara Hero, Anne Welte, Yvonne Kahlert, Andrea Roderwieser, Christoph Bartenhagen, Esther Walter, Judith Gecht, Laura Kerschke, Ruth Volland, Roopika Menon, Johannes M Heuckmann, Moritz Gartlgruber, Sabine Hartlieb, Kai-Oliver Henrich, Konstantin Okonechnikov, Janine Altmüller, Peter Nürnberg, Steve Lefever, Bram De Wilde, Frederik Sand, Fakhera Ikram, Carolina Rosswog, Janina Fischer, Jessica Theissen, Falk Hertwig, Aatur D Singhi, Thorsten Simon, Wenzel Vogel, Sven Perner, Barbara Krug, Matthias Schmidt, Sven Rahmann, Viktor Achter, Ulrich Lang, Christian Vokuhl, Monika Ortmann, Reinhard Büttner, Angelika Eggert, Frank Speleman, Roderick J O'Sullivan, Roman K Thomas, Frank Berthold, Jo Vandesompele, Alexander Schramm, Frank Westermann, Johannes H Schulte, Martin Peifer, Matthias Fischer
A mechanistic classification of clinical phenotypes in neuroblastoma. Science (New York, N.Y.) 362 (6419) (2019)
Katharina Batzke, Gabriele Büchel, Wiebke Hansen, Alexander Schramm
TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy. International journal of molecular sciences 19 (3) (2018)
Marc Schulte, Johannes Köster, Sven Rahmann, Alexander Schramm
Cancer evolution, mutations, and clonal selection in relapse neuroblastoma. Cell and tissue research 372 (2) (2018)
Lucas Moreno, Hubert Caron, Birgit Geoerger, Angelika Eggert, Gudrun Schleiermacher, Penelope Brock, Dominique Valteau-Couanet, Louis Chesler, Johannes H Schulte, Katleen De Preter, Jan Molenaar, Alexander Schramm, Martin Eilers, Tom Van Maerken, John Inge Johnsen, Michelle Garrett, Sally L George, Deborah A Tweddle, Per Kogner, Frank Berthold, Jan Koster, Giuseppe Barone, Elizabeth R Tucker, Lynley Marshall, Ralf Herold, Jaroslav Sterba, Koen Norga, Gilles Vassal, Andrew Dj Pearson
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert opinion on drug discovery 12 (8) (2017)
Jan Müller, Robin Reichel, Sebastian Vogt, Stefan P Müller, Wolfgang Sauerwein, Wolfgang Brandau, Angelika Eggert, Alexander Schramm
Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. PloS one 11 (10) (2016)
Alexander Schramm, Johannes Köster, Yassen Assenov, Kristina Althoff, Martin Peifer, Ellen Mahlow, Andrea Odersky, Daniela Beisser, Corinna Ernst, Anton G Henssen, Harald Stephan, Christopher Schröder, Lukas Heukamp, Anne Engesser, Yvonne Kahlert, Jessica Theissen, Barbara Hero, Frederik Roels, Janine Altmüller, Peter Nürnberg, Kathy Astrahantseff, Christian Gloeckner, Katleen De Preter, Christoph Plass, Sangkyun Lee, Holger N Lode, Kai-Oliver Henrich, Moritz Gartlgruber, Frank Speleman, Peter Schmezer, Frank Westermann, Sven Rahmann, Matthias Fischer, Angelika Eggert, Johannes H Schulte
Mutational dynamics between primary and relapse neuroblastomas. Nature genetics 47 (8) (2015)

Alexander Schramm.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Alexander Schramm